ホーム › がん（全種類） › マサチューセッツ州 › Boston
Boston、MAにおけるがん（全種類）の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、がん（全種類）に関する86件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Distance-Based Exercise to Preserve Function and Prevent Disability
被験者募集中
- Dana-Farber Cancer Institute, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
被験者募集中第1相
- Beth Israel Deaconess Medical Center - Research, Boston
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
被験者募集中観察研究
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
被験者募集中第1相
- Massachusetts General Hospital, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Boston
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
被験者募集中第3相
- Investigative Site, Boston
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
被験者募集中第1/2相
- Dana Farber Cancer Center ( Site 4013), Boston
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
被験者募集中第3相
- Dana Farber/Harvard Cancer Center, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
被験者募集中
- Massachusetts General Hospital, Boston
Pan Tumor Rollover Study
被験者募集中第2相
- Dana_Farber Cancer Institute (DFCI), Boston
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
被験者募集中第3相
- Beth Israel Deaconess Medical Center ( Site 0107), Boston
- Dana-Farber Cancer Institute ( Site 0105), Boston
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
被験者募集中第3相
- Dana-Farber Cancer Institute /ID# 279690, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
被験者募集中第2/3相
- Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
被験者募集中第1/2相
- Dana-Farber Cancer Institute ( Site 3013), Boston
Statins to Prevent Cancer Associated Blood Clots
被験者募集中第4相
- Beth Isreal Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors
被験者募集中
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs
被験者募集中
- Dana-Farber Cancer Institute, Boston
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
被験者募集中第1/2相
- Dana-Farber Cancer Institute /ID# 271846, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
被験者募集中第1/2相
- Research Site, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Boston Medical Center, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
被験者募集中観察研究
- Dana Farber Cancer Institute, Boston
Lurbinectedin in FET-Fused Tumors
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Prostate Active Surveillance Study
被験者募集中観察研究
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital (MG), Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
被験者募集中第1相
- Massachusetts General Hospital, Boston
BRIDGE-SIC Efficacy Trial
被験者募集中
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Abatacept in Immune Checkpoint Inhibitor Myocarditis
被験者募集中第3相
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Boston Medical Center, Boston
- 他1件
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital Cancer Center, Boston
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
被験者募集中第1相健康なボランティア歓迎
- Boston Medical Center, Boston
- Massachusetts General Hospital (MGH), Charlestown · 1マイル先
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
被験者募集中第1相
- Brigham and Women's Hospital, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
被験者募集中第2相
- Massachusetts General Hospital /ID# 273608, Boston
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The STOP-MED CTRCD Trial
被験者募集中第4相
- Brigham and Women's Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
被験者募集中第1相
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Childhood Cancer Survivor Study
被験者募集中観察研究健康なボランティア歓迎
- Dana-Farber Cancer Institute, Boston
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
被験者募集中
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Boston
- Research Site, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
被験者募集中第1相
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Multisite Implementation of COMPRENDO
被験者募集中健康なボランティア歓迎
- Dana Farber Cancer Institute/Boston Children's Hospital, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
被験者募集中第1相
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
被験者募集中第1/2相
- Massachusetts General Hospital,, Boston
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
被験者募集中第1相
- GSK Investigational Site, Boston
Video Inspired Discussions About Ethical Outcomes in Pediatrics
被験者募集中
- Dana Farber Cancer Institute, Boston
On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
被験者募集中参加者への支払いあり
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
Intraoperative Tumor Margin Identification With ICG Dye Imaging
被験者募集中第2相
- Massachusetts General Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
Suprachoroidal Administration in Subjects With Metastases to the Choroid
被験者募集中第2相
- Massachusetts Eye and Ear, Boston
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
被験者募集中
- Dana-Farber Cancer Institute, Boston
Positron Emission Tomography (PET) Imaging of Thrombosis
被験者募集中第1相健康なボランティア歓迎
- Massachusetts General Hospital, Boston
Primary Tumor Research and Outcomes Network
被験者募集中観察研究
- Massachusetts General Hospital, Boston
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
被験者募集中
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
PediRISE Feasibility
被験者募集中
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
被験者募集中第2相
- Dana-Farber Cancer Institute /ID# 230061, Boston
A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers
被験者募集中
- Massachusetts General Hospital Cancer Center, Boston
A Study of YL242 in Subjects With Advanced Solid Tumors
被験者募集中第1/2相
- US-204, Boston
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
被験者募集中観察研究
- Boston Children's Hospital, Boston
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
被験者募集中健康なボランティア歓迎
- Codman Square Health Center, Boston
- East Boston Neighborhood Health Center, East Boston · 2マイル先
Childhood Cancer Predisposition Study (CCPS)
被験者募集中観察研究
- Dana Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
被験者募集中
- Massachusetts General Hospital Cancer Center, Boston
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
被験者募集中観察研究
- Massachusetts General Hospital, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
被験者募集中
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
被験者募集中第1/2相
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
被験者募集中健康なボランティア歓迎
- Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
被験者募集中第3相
- Massachusetts General Hospital, Boston
他の都市におけるがん（全種類）の試験
- Houston, TX121件の研究
- New York City, NY110件の研究
- Los Angeles, CA73件の研究
- Nashville, TN65件の研究
- Philadelphia, PA59件の研究
- Durham, NC58件の研究
- Washington, DC58件の研究
- Chicago, IL51件の研究
- Seattle, WA49件の研究
- Atlanta, GA49件の研究
- Arlington, VA48件の研究
- St. Louis, MO46件の研究
Bostonにおける他の研究
- 乳がん111件の研究
- 非小細胞肺癌90件の研究
- 大腸癌63件の研究
- 転移性癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
- 膵臓がん43件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。